Working title: Molecular involvement of p53‐MDM2 interactome in gastrointestinal cancers.

The interaction between murine double minute 2 (MDM2) and p53, marked by transcriptional induction and feedback inhibition, orchestrates a functional loop dictating cellular fate. The functional loop comprising p53‐MDM2 axis is made up of an interactome consisting of approximately 81 proteins, which are spatio‐temporally regulated and involved in DNA repair mechanisms. Biochemical and genetic alterations of the interactome result in dysregulation of the p53‐mdm2 axis that leads to gastrointestinal (GI) cancers. A large subset of interactome is well known and it consists of proteins that either stabilize p53 or MDM2 and proteins that target the p53‐MDM2 complex for ubiquitin‐mediated destruction. Upstream signaling events brought about by growth factors and chemical messengers invoke a wide variety of posttranslational modifications in p53‐MDM2 axis. Biochemical changes in the transactivation domain of p53 impact the energy landscape, induce conformational switching, alter interaction potential and could change solubility of p53 to redefine its co‐localization, translocation and activity. A diverse set of chemical compounds mimic physiological effectors and simulate biochemical modifications of the p53‐MDM2 interactome. p53‐MDM2 interactome plays a crucial role in DNA damage and repair process. Genetic aberrations in the interactome, have resulted in cancers of GI tract (pancreas, liver, colorectal, gastric, biliary, and esophageal). We present in this article a review of the overall changes in the p53‐MDM2 interactors and the effectors that form an epicenter for the development of next‐generation molecules for understanding and targeting GI cancers. Significance Statement: This manuscript presents, a thorough analysis and dissection of p53‐MDM2 interactome, its regulation and genetic involvement in Cancers of GI tract. The manuscript also discusses about chemical biology of the p53 axis and how this can be translated to understand therapeutic aspects of the current understanding in cancer biology for cancer treatment. [ABSTRACT FROM AUTHOR]